ZAI LAB (09688) total revenue for the first quarter was 99.6 million US dollars.

ZAI LAB (09688) announced that the total revenue for the first quarter of 2026 was $99.6 million, compared to $106.5 million in the same period in 2025, a decrease of 6%. The net product revenue for the first quarter of 2026 was $95.6 million, compared to $105.7 million in the same period in 2025, a decrease of 10%, or 12% when calculated at Constant Exchange Rates (CER). The net loss for the first quarter of 2026 was $51 million, with a loss per share of $0.05 for ordinary shareholders. Dr. Samantha Du, founder, chairman, and CEO of ZAI LAB, stated: "We are accelerating the development of our global pipeline, with several clinical studies underway in the fields of oncology and immunology. In the first quarter, we made significant progress with zoci: further data presented at AACR confirmed zoci's differentiated advantages in SCLC and epNECs; we formed partnerships with Amgen and Boehringer Ingelheim to explore the potential applications of zoci as a foundational therapy; enrollment in the registrational study DLLEVATE is progressing rapidly, with completion expected in the first half of 2027. We are also advancing our expanding global clinical research projects, including ZL-1503 for atopic dermatitis. These advancements showcase the strength of our research and development engine, which is built to scale and create a differentiated innovative product pipeline. At the same time, our regionally profitable commercial business provides a solid foundation for the company, along with multiple opportunities to support future growth." Josh Smiley, president and COO of ZAI LAB, stated: "We are deepening our presence in key markets to meet potential demand for Agemood, while expanding our regional business coverage to prepare for the launch of Deutidezylammonium in China in the second quarter of this year. With around 8 million schizophrenia patients in China, the launch of Deutidezylammonium, supported by national treatment guidelines, will allow us to introduce the first new therapy in decades to this important market, with hopes of inclusion in the national medical insurance drug list next year. Additionally, we expect the market approval of TIVDAK this year, and positive results from phase 3 studies of povetacicept and elegrobart, which will bring more growth opportunities to the company. We will continue to focus on driving steady execution across our entire commercial product portfolio."